Project Grant P01HL183483
Award Date 9/5/25
Completion Date 6/30/30
Dollars Obligated $3.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This Project Grant award of $343,744 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of a comprehensive strategy for an Investigational New Drug (IND) submission and clinical development of a hematopoietic stem/progenitor cell-based chimeric antigen receptor (CAR) gene therapy to functionally cure HIV infection. The key products and services to be delivered include: 1) Formulating a strategic plan...
- The University of Southern California received a $162,486 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to engineer B cells for enhanced HIV control. The 4.5-year project, which began on February 1, 2025, aims to develop an approach to provide necessary T cell help and produce broadly neutralizing antibody-engineered B cells that would be functional in people living with HIV. Key objectives include...
- This Project Grant award for $3,643,653.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program, aims to generate a chimeric antigen receptor (CAR) approach that can control HIV viral replication and eliminate the viral reservoir. The award supports four key projects: Engineering viral-specific T cells with improved function and persistence for chronic HIV infection (Project 1). Developing an...
- The National Heart Lung and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, awarded a $3,519,835 Project Grant to the Scripps Research Institute in La Jolla, CA on September 5, 2025. The grant, titled "PLANB2CUREHIV (THE 'PLANB' CONSORTIUM) - PROJECT SUMMARY", aims to accelerate the preclinical development of safe and effective genome-edited B cell-based therapies that could provide long-lasting, broadly neutralizing antibody titers capable of...
- This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $250,000 to the University of Alabama at Birmingham (UAB) to develop novel cell and gene therapy approaches for an HIV cure. The project aims to demonstrate that HLA-E-peptide complexes on HIV-infected cells can be targeted by antibodies, natural killer cells, or genetically engineered CD8+ T cells, leading to the destruction and clearance of the...
- This Project Grant award of $1,657,972 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to characterize allogeneic T cell responses that may mediate a functional cure for HIV. The research, conducted by Oregon Health & Science University (OHSU), aims to define the allogeneic T cell responses and their targets in individuals cured of HIV after allogeneic hematopoietic stem cell...
- This $118,488 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on January 20, 2025, supports research to develop HIV-resistant hematopoietic stem cells through targeted base editing. The project aims to identify genetic mutations in the CCR5 and CXCR4 co-receptors that can prevent HIV entry into CD4 cells while maintaining the central functions of these proteins in hematopoiesis. The research involves...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $249,000 to support research focused on developing gene-edited primary human cells that can enhance HIV-1 resistance. The research aims to achieve greater than 90% deletion of the CCR5 co-receptor and up to 50% allelic knock-in of inhibitory peptides targeting viral fusion and uncoating, resulting in significant inhibition of both CCR5- and CXCR4-tropic HIV...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is providing $919,501 to Emmune Inc. to develop a non-viral gene therapy platform using ECD4-IG, an antibody-like therapeutic protein, to suppress HIV replication for a lifetime after a single intramuscular injection. The goal is to achieve a functional cure for HIV by sustaining therapeutically-effective plasma...
- This Project Grant award of $486,057 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a multipronged mRNA gene therapy approach to address challenges in achieving an HIV cure. The award aims to develop three novel mRNA-based interventions: targeted delivery of the viral protein Tat to activate HIV transcription, hepatic delivery of mRNA encoding HIV-neutralizing...